Do analysts rate MWYN or BGMS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marwynn 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate BGMS or TLIH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ten-League International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, BGMS or TLIH?

Ten-League International has higher revenue and earnings than Cyclacel Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cyclacel Pharmaceuticals $750K 6.61 -$3M -$3.64 N/A Ten-League International $59.24M 0.29 $4.34M N/A N/A

Do analysts rate BGMS or CLWT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Euro Tech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, BGMS or CLWT?

Euro Tech has higher revenue and earnings than Cyclacel Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cyclacel Pharmaceuticals $750K 6.61 -$3M -$3.64 N/A Euro Tech $13.27M 0.89 $160K N/A N/A

Do analysts prefer SOS or BGMS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SOS 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, SOS or BGMS?

Cyclacel Pharmaceuticals has lower revenue, but higher earnings than SOS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SOS $154.29M 0.08 -$97.32M N/A N/A Cyclacel Pharmaceuticals $750K 6.61 -$3M -$3.64 N/A

Do analysts recommend BGMS or JBDI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 JBDI 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, BGMS or JBDI?

JBDI has higher revenue and earnings than Cyclacel Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cyclacel Pharmaceuticals $750K 6.61 -$3M -$3.64 N/A JBDI $8.52M 1.38 $120K N/A N/A

Does the media refer more to BGMS or JBDI?

In the previous week, Cyclacel Pharmaceuticals had 3 more articles in the media than JBDI. MarketBeat recorded 5 mentions for Cyclacel Pharmaceuticals and 2 mentions for JBDI. JBDI's average media sentiment score of 1.11 beat Cyclacel Pharmaceuticals' score of 0.72 indicating that JBDI is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cyclacel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive JBDI 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Trading of Cyclacel Pharmaceuticals was halted at 10:28 AM EST due to "LULD Pause".

Cyclacel Pharmaceuticals (BGMS) Competitors

$0.90 +0.03 (+2.94%)

Closing price 04:00 PM Eastern

Extended Trading

$0.89 -0.01 (-1.18%)

As of 07:55 PM Eastern

Compare

BGMS vs. MWYN, TLIH, CLWT, SOS, and JBDI

Should you buy Cyclacel Pharmaceuticals stock or one of its competitors? Cyclacel Pharmaceuticals's main competitors and comparable companies include Marwynn (MWYN), Ten-League International (TLIH), Euro Tech (CLWT), SOS (SOS), and JBDI (JBDI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "trading companies & distributors" industry.

How does Cyclacel Pharmaceuticals compare to Marwynn?

Marwynn (NASDAQ:MWYN) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap industrials companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

In the previous week, Cyclacel Pharmaceuticals had 3 more articles in the media than Marwynn. MarketBeat recorded 5 mentions for Cyclacel Pharmaceuticals and 2 mentions for Marwynn. Cyclacel Pharmaceuticals' average media sentiment score of 0.72 beat Marwynn's score of 0.46 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Marwynn	Neutral
Cyclacel Pharmaceuticals	Positive

Marwynn has a beta of 3.81, meaning that its share price is 281% more volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, meaning that its share price is 140% less volatile than the broader market.

Cyclacel Pharmaceuticals has lower revenue, but higher earnings than Marwynn. Marwynn is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marwynn	$4.24M	4.76	-$3.92M	-$0.22	N/A
Cyclacel Pharmaceuticals	$750K	6.61	-$3M	-$3.64	N/A

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 29.8% of Marwynn shares are owned by company insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Marwynn has a net margin of -59.88% compared to Cyclacel Pharmaceuticals' net margin of -118.27%. Cyclacel Pharmaceuticals' return on equity of -31.60% beat Marwynn's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marwynn	-59.88%	-134.21%	-45.24%
Cyclacel Pharmaceuticals	-118.27%	-31.60%	-27.72%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marwynn	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cyclacel Pharmaceuticals beats Marwynn on 8 of the 13 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Ten-League International?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Ten-League International (NASDAQ:TLIH) are both small-cap industrials companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Ten-League International has higher revenue and earnings than Cyclacel Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	6.61	-$3M	-$3.64	N/A
Ten-League International	$59.24M	0.29	$4.34M	N/A	N/A

Ten-League International has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -118.27%. Ten-League International's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	-118.27%	-31.60%	-27.72%
Ten-League International	N/A	N/A	N/A

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ten-League International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cyclacel Pharmaceuticals has a beta of -0.4, indicating that its stock price is 140% less volatile than the broader market. Comparatively, Ten-League International has a beta of 2.38, indicating that its stock price is 138% more volatile than the broader market.

In the previous week, Cyclacel Pharmaceuticals had 3 more articles in the media than Ten-League International. MarketBeat recorded 5 mentions for Cyclacel Pharmaceuticals and 2 mentions for Ten-League International. Ten-League International's average media sentiment score of 1.43 beat Cyclacel Pharmaceuticals' score of 0.72 indicating that Ten-League International is being referred to more favorably in the news media.

Company	Overall Sentiment
Cyclacel Pharmaceuticals	Positive
Ten-League International	Positive

Summary

Ten-League International beats Cyclacel Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Euro Tech?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Euro Tech (NASDAQ:CLWT) are both small-cap industrials companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Cyclacel Pharmaceuticals has a beta of -0.4, indicating that its stock price is 140% less volatile than the broader market. Comparatively, Euro Tech has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

In the previous week, Cyclacel Pharmaceuticals had 3 more articles in the media than Euro Tech. MarketBeat recorded 5 mentions for Cyclacel Pharmaceuticals and 2 mentions for Euro Tech. Euro Tech's average media sentiment score of 1.44 beat Cyclacel Pharmaceuticals' score of 0.72 indicating that Euro Tech is being referred to more favorably in the news media.

Company	Overall Sentiment
Cyclacel Pharmaceuticals	Positive
Euro Tech	Positive

Euro Tech has higher revenue and earnings than Cyclacel Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	6.61	-$3M	-$3.64	N/A
Euro Tech	$13.27M	0.89	$160K	N/A	N/A

Euro Tech has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -118.27%. Euro Tech's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	-118.27%	-31.60%	-27.72%
Euro Tech	N/A	N/A	N/A

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 2.9% of Euro Tech shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by company insiders. Comparatively, 79.0% of Euro Tech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Euro Tech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Euro Tech beats Cyclacel Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to SOS?

SOS (NYSE:SOS) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap industrials companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Cyclacel Pharmaceuticals had 5 more articles in the media than SOS. MarketBeat recorded 5 mentions for Cyclacel Pharmaceuticals and 0 mentions for SOS. Cyclacel Pharmaceuticals' average media sentiment score of 0.72 beat SOS's score of 0.00 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
SOS	Neutral
Cyclacel Pharmaceuticals	Positive

Cyclacel Pharmaceuticals has lower revenue, but higher earnings than SOS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOS	$154.29M	0.08	-$97.32M	N/A	N/A
Cyclacel Pharmaceuticals	$750K	6.61	-$3M	-$3.64	N/A

SOS has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -118.27%. SOS's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOS	N/A	N/A	N/A
Cyclacel Pharmaceuticals	-118.27%	-31.60%	-27.72%

SOS has a beta of 2.6, indicating that its share price is 160% more volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, indicating that its share price is 140% less volatile than the broader market.

1.9% of SOS shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 2.7% of SOS shares are owned by insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOS	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cyclacel Pharmaceuticals beats SOS on 6 of the 11 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to JBDI?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and JBDI (NASDAQ:JBDI) are both small-cap industrials companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

In the previous week, Cyclacel Pharmaceuticals had 3 more articles in the media than JBDI. MarketBeat recorded 5 mentions for Cyclacel Pharmaceuticals and 2 mentions for JBDI. JBDI's average media sentiment score of 1.11 beat Cyclacel Pharmaceuticals' score of 0.72 indicating that JBDI is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cyclacel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
JBDI	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cyclacel Pharmaceuticals has a beta of -0.4, suggesting that its share price is 140% less volatile than the broader market. Comparatively, JBDI has a beta of -1.11, suggesting that its share price is 211% less volatile than the broader market.

JBDI has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -118.27%. JBDI's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	-118.27%	-31.60%	-27.72%
JBDI	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
JBDI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

JBDI has higher revenue and earnings than Cyclacel Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	6.61	-$3M	-$3.64	N/A
JBDI	$8.52M	1.38	$120K	N/A	N/A

Summary

JBDI beats Cyclacel Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get Cyclacel Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGMS vs. The Competition

Export

Metric	Cyclacel Pharmaceuticals	Trading Companies & Distributors Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$4.81M	$9.26B	$10.31B	$13.98B
Dividend Yield	N/A	3.49%	97.17%	11.70%
P/E Ratio	-0.25	27.00	25.56	25.37
Price / Sales	6.61	22.43	328.08	70.35
Price / Cash	N/A	47.45	23.85	34.96
Price / Book	0.64	3.71	4.83	6.24
Net Income	-$3M	$372.29M	$612.13M	$358.08M
7 Day Performance	-0.27%	-2.03%	0.08%	-1.43%
1 Month Performance	-1.90%	-5.92%	-3.58%	-2.71%
1 Year Performance	N/A	4.19%	5.68%	8.46%

Cyclacel Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGMS Cyclacel Pharmaceuticals	1.1743 of 5 stars	$0.90 +2.9%	N/A	N/A	$4.81M	$750K	N/A	14	Short Interest Decrease Gap Down Trading Halted High Trading Volume
MWYN Marwynn	0.5927 of 5 stars	$0.93 +5.8%	N/A	-21.8%	$17.74M	$4.24M	N/A	27	Positive News Earnings Report Gap Up
TLIH Ten-League International	1.0247 of 5 stars	$5.80 +1.7%	N/A	-0.4%	$16.76M	$59.24M	N/A	64	Positive News Short Interest Decrease
CLWT Euro Tech	1.2265 of 5 stars	$1.55 -8.3%	N/A	+0.0%	$12.59M	$13.27M	N/A	40	Positive News Short Interest Decrease Gap Down High Trading Volume
SOS SOS	0.3533 of 5 stars	$0.75 -2.9%	N/A	-58.4%	$12.41M	$154.29M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGMS) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cyclacel Pharmaceuticals (BGMS) Competitors

BGMS vs. MWYN, TLIH, CLWT, SOS, and JBDI

How does Cyclacel Pharmaceuticals compare to Marwynn?

Summary

How does Cyclacel Pharmaceuticals compare to Ten-League International?

Summary

How does Cyclacel Pharmaceuticals compare to Euro Tech?

Summary

How does Cyclacel Pharmaceuticals compare to SOS?

Summary

How does Cyclacel Pharmaceuticals compare to JBDI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGMS vs. The Competition

Cyclacel Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cyclacel Pharmaceuticals (BGMS) Competitors

BGMS vs. MWYN, TLIH, CLWT, SOS, and JBDI

How does Cyclacel Pharmaceuticals compare to Marwynn?

Does the media prefer MWYN or BGMS?

Which has more risk and volatility, MWYN or BGMS?

Which has higher earnings & valuation, MWYN or BGMS?

Do insiders and institutionals believe in MWYN or BGMS?

Is MWYN or BGMS more profitable?

Do analysts rate MWYN or BGMS?

Summary

How does Cyclacel Pharmaceuticals compare to Ten-League International?

Which has better earnings and valuation, BGMS or TLIH?

Is BGMS or TLIH more profitable?

Do institutionals & insiders have more ownership in BGMS or TLIH?

Do analysts rate BGMS or TLIH?

Which has more volatility and risk, BGMS or TLIH?

Does the media refer more to BGMS or TLIH?

Summary

How does Cyclacel Pharmaceuticals compare to Euro Tech?

Which has more volatility and risk, BGMS or CLWT?

Does the media refer more to BGMS or CLWT?

Which has better earnings and valuation, BGMS or CLWT?

Is BGMS or CLWT more profitable?

Do institutionals & insiders have more ownership in BGMS or CLWT?

Do analysts rate BGMS or CLWT?

Summary

How does Cyclacel Pharmaceuticals compare to SOS?

Does the media prefer SOS or BGMS?

Which has stronger valuation and earnings, SOS or BGMS?

Is SOS or BGMS more profitable?

Which has more volatility and risk, SOS or BGMS?

Do insiders and institutionals have more ownership in SOS or BGMS?

Do analysts prefer SOS or BGMS?

Summary

How does Cyclacel Pharmaceuticals compare to JBDI?

Does the media refer more to BGMS or JBDI?

Do insiders and institutionals have more ownership in BGMS or JBDI?

Which has more volatility & risk, BGMS or JBDI?

Is BGMS or JBDI more profitable?

Do analysts recommend BGMS or JBDI?

Which has preferable earnings & valuation, BGMS or JBDI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGMS vs. The Competition

Cyclacel Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools